BioAge Labs Inc. Common Stock (BIOA)
Stock · NASDAQ · Health Care
$4.81as of 10/16/2026
Price chart
Active signals
BIOA Signal Track Record
How signals performed across all stocks →What BIOA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 13 | +14.6% | 85% | October 6, 2026 |
| Bollinger Band Breakout | 8 | +9.1% | 63% | June 12, 2026 |
| Bollinger Band BreakdownActive now | 5 | +14.0% | 80% | September 10, 2026 |
| Any 20-session window (baseline) | +7.6% | 60% |
Computed by MarketWall from daily closing prices since July 16, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BIOA
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phas…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 60
- Website
- bioagelabs.com
Fundamentals
- 1-day range
- $4.81$5.35
- Market cap
- $500.98M
- P/E (trailing)
- —
- P/E (forward)
- -1.93
- EPS (trailing)
- $-2.39
- Dividend yield
- —
- Beta
- 2.33
- Avg. volume
- 931.7K
How BioAge Labs Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 24, 2026 · via SEC EDGAR / Finnhub
Forecasts
9 analyst ratings
BioAge Labs Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BIOABioAge Labs Inc. Common Stock$4.84▼ 9.53%Market cap $500.98MP/E —$5.04$25.96
- TENXTenax Therapeutics Inc. Common Stock$1.36▼ 9.93%Market cap $498.11MP/E —$1.31$19.4
- OVIDOvid Therapeutics Inc. Common Stock$2.15▼ 4.87%Market cap $494.60MP/E —$1.18$3.11
- AQSTAquestive Therapeutics Inc. Common Stock$3.78▼ 6.90%Market cap $491.83MP/E —$2.93$7.55
- EOLSEvolus Inc. Common Stock$7.1▼ 6.21%Market cap $487.98MP/E —$3.86$9.31
- VSTMVerastem Inc. Common Stock$8.65▼ 6.28%Market cap $519.33MP/E —$3.43$10.82
- QTTBQ32 Bio Inc. Common Stock$7.52▼ 3.22%Market cap $482.18MP/E 7.95$1.91$23.57
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BIOA BioAge Labs Inc. Common Stock | $500.98M | — | $4.84 | ▼ 9.53% | $5.04$25.96 |
| TENX Tenax Therapeutics Inc. Common Stock | $498.11M | — | $1.36 | ▼ 9.93% | $1.31$19.4 |
| OVID Ovid Therapeutics Inc. Common Stock | $494.60M | — | $2.15 | ▼ 4.87% | $1.18$3.11 |
| AQST Aquestive Therapeutics Inc. Common Stock | $491.83M | — | $3.78 | ▼ 6.90% | $2.93$7.55 |
| EOLS Evolus Inc. Common Stock | $487.98M | — | $7.1 | ▼ 6.21% | $3.86$9.31 |
| VSTM Verastem Inc. Common Stock | $519.33M | — | $8.65 | ▼ 6.28% | $3.43$10.82 |
| QTTB Q32 Bio Inc. Common Stock | $482.18M | 7.95 | $7.52 | ▼ 3.22% | $1.91$23.57 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8benzinga · 10/12/2026
- BioAge Labs to Present at Upcoming Investor ConferencesYahoo · 9/25/2026
- 10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga · 9/25/2026
- BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Barton Shane · June 30, 2026 · Option Exercise7.9K @ $4.38
- Barton Shane · June 30, 2026 · Option Exercise4.1K @ $4.3
- Barton Shane · June 30, 2026 · Option Exercise4.0K @ $8.39
- Barton Shane · June 30, 2026 · Option Exercise4.3K @ $10.85
- Barton Shane · June 30, 2026 · Sale20.2K @ $25.19
- Barton Shane · June 29, 2026 · Option Exercise14.2K @ $4.38
- Barton Shane · June 29, 2026 · Option Exercise9.0K @ $4.3
- Barton Shane · June 29, 2026 · Option Exercise7.3K @ $8.39
- Barton Shane · June 29, 2026 · Option Exercise9.3K @ $10.85
- Barton Shane · June 29, 2026 · Sale42.4K @ $25.21
- Pande Vijay Satyanand · June 10, 2026 · Grant22.0K
- Rekha Hemrajani · June 10, 2026 · Grant22.0K
- Michael H. Davidson · June 10, 2026 · Grant22.0K
- Patrick G. Enright · June 10, 2026 · Grant22.0K
- James Healy · June 10, 2026 · Grant22.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 33.73M
- Total value held
- $581.41M
- Institutional holders
- 142
- Unknown3.23M
- Unknown2.89M
- Unknown2.29M
- Unknown2.27M
- Unknown2.09M
- Unknown1.75M
- Unknown1.65M
- Unknown1.35M
- Unknown1.33M
- Unknown1.20M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
BioAge Labs to Present at Investor Conferences
BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.
BioAge Labs to Present at Investor Conferences. BioAge Labs announced it will present at upcoming investor conferences, providing a platform to share company updates with the market. The stock is currently trading near its 52-week low, which may increase attention from investors seeking value. This corporate activity adds context to the recent whale alerts noted in healthcare stocks.